AOD-9604

AOD-9604 (Advanced Obesity Drug 9604)

Primary Function: Fat metabolism, lipolysis stimulation, anti-obesity research
Research Use: Weight loss studies, cartilage repair, metabolic regulation
Molecular Formula: C78H123N23O23S2
CAS Number: 221231-10-3
Synonyms: HGH Fragment 176-191, Anti-Obesity Peptide, AOD

Description:
AOD-9604 is a synthetic fragment of human growth hormone (HGH 176-191), developed to isolate the fat-burning properties of HGH without affecting blood sugar or IGF-1 levels. It selectively stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a leading research candidate for obesity, metabolic disorders, and joint repair applications. Unlike full-length HGH, AOD-9604 does not promote muscle growth or impact insulin sensitivity, making it highly specific for fat metabolism.

Mechanism of Action:

• Activates beta-3 adrenergic receptors on adipocytes to promote lipolysis
• Reduces lipogenesis by downregulating fat storage enzymes
• Exhibits regenerative effects in cartilage and bone models
• Lacks effect on blood glucose and IGF-1—non-anabolic profile

Key Research Areas:

• Obesity and weight management
• Metabolic syndrome and insulin resistance
• Osteoarthritis and cartilage regeneration
• Non-anabolic fat reduction studies

History of Discovery:
AOD-9604 was developed in the early 2000s by Metabolic Pharmaceuticals in Australia as part of a therapeutic program targeting obesity without hormonal side effects. Derived from the C-terminal end of HGH, it maintains the fat-reducing segment while eliminating the growth-promoting properties of the full hormone, creating a safer and more targeted research molecule.

Case Studies:

1. Fat Reduction Without IGF-1 Elevation (2004, Obesity Research): Daily oral and injectable AOD-9604 led to measurable weight loss in obese participants without altering insulin or IGF-1. [Obes Res. 2004;12(7):1126–1134.]
2. Cartilage Regeneration Support (2010, Bone & Joint J): AOD-9604 promoted chondrocyte proliferation and matrix repair in osteoarthritic joints. [Bone Joint J. 2010;92-B(6):857–862.]
3. Safety and Tolerability in Humans (2008, Clin Pharmacol Ther): Multiple-dose Phase 1 trials found no significant side effects or hormonal changes in healthy volunteers. [Clin Pharmacol Ther. 2008;83(2):203–207.]

Packaging Information:

• Form: Lyophilized powder
• Purity: ≥ 99%
• Storage: Store at -20°C in a dry, dark environment
• For research use only. Not for human or veterinary use.